Lee M Fidler, Joseph S Munn, Jolene H Fisher, Shane Shapera, Andrea S Gershon
{"title":"Hospitalization Trends and Risk Factors in Rheumatoid Arthritis-Related Interstitial Lung Disease: An Observational Study From Ontario, Canada.","authors":"Lee M Fidler, Joseph S Munn, Jolene H Fisher, Shane Shapera, Andrea S Gershon","doi":"10.1016/j.chest.2025.05.030","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis-related interstitial lung disease (RA-ILD) represents an important disease manifestation of rheumatoid arthritis. A scarcity of population-level information on hospitalization rates in RA-ILD exists.</p><p><strong>Research question: </strong>What are the current rates and trends in all-cause and RA-ILD-related hospitalizations in patients with RA-ILD?</p><p><strong>Study design and methods: </strong>We performed a retrospective observational study using health services data from Ontario, Canada, between 2003 and 2022. We identified people with RA-ILD using the Ontario Rheumatoid Arthritis Database and required repeated physician claims for interstitial lung disease before cohort entry. We estimated age- and sex-standardized annual all-cause and RA-ILD-related hospitalization rates during the study period. We performed multivariable logistic regression to ascertain factors associated with an RA-ILD diagnosis during a hospitalization and generated a Fine-Gray subdistribution hazards model with competing risk to assess the time to RA-ILD-related hospitalization.</p><p><strong>Results: </strong>We identified 7,075 people with RA-ILD during the cohort period. Standardized all-cause hospitalization rates increased from 6.4 to 12.9 admissions per 100,000 people between 2003 and 2022 (101% increase; P < .001). RA-ILD-related hospitalizations increased from 2.6 to 3.5 admissions per 100,000 people (37% increase; P = .045). In-hospital mortality from RA-ILD-related admissions was 19.5 deaths per 100 admissions in 2022, having remained stable over time (P = .62). Patients in the lowest income quintile (OR, 1.35 [95% CI, 1.06-1.72]; P = .02) and residing in rural areas (OR, 1.37 [95% CI, 1.11-1.70]; P = .004) were more likely to receive a diagnosis of RA-ILD during a hospitalization. Patients who received a diagnosis of RA-ILD during a hospitalization showed an increased hazard for future RA-ILD-related admissions (hazard ratio, 1.44 [1.24-1.68]; P < .001).</p><p><strong>Interpretation: </strong>All-cause and RA-ILD-related hospitalizations are increasing. In-hospital mortality has not changed over time, but remains substantial. Socioeconomic factors are associated with receiving an RA-ILD diagnosis in the hospital, which seems to be an important risk factor for future RA-ILD-related admissions.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":8.6000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2025.05.030","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Rheumatoid arthritis-related interstitial lung disease (RA-ILD) represents an important disease manifestation of rheumatoid arthritis. A scarcity of population-level information on hospitalization rates in RA-ILD exists.
Research question: What are the current rates and trends in all-cause and RA-ILD-related hospitalizations in patients with RA-ILD?
Study design and methods: We performed a retrospective observational study using health services data from Ontario, Canada, between 2003 and 2022. We identified people with RA-ILD using the Ontario Rheumatoid Arthritis Database and required repeated physician claims for interstitial lung disease before cohort entry. We estimated age- and sex-standardized annual all-cause and RA-ILD-related hospitalization rates during the study period. We performed multivariable logistic regression to ascertain factors associated with an RA-ILD diagnosis during a hospitalization and generated a Fine-Gray subdistribution hazards model with competing risk to assess the time to RA-ILD-related hospitalization.
Results: We identified 7,075 people with RA-ILD during the cohort period. Standardized all-cause hospitalization rates increased from 6.4 to 12.9 admissions per 100,000 people between 2003 and 2022 (101% increase; P < .001). RA-ILD-related hospitalizations increased from 2.6 to 3.5 admissions per 100,000 people (37% increase; P = .045). In-hospital mortality from RA-ILD-related admissions was 19.5 deaths per 100 admissions in 2022, having remained stable over time (P = .62). Patients in the lowest income quintile (OR, 1.35 [95% CI, 1.06-1.72]; P = .02) and residing in rural areas (OR, 1.37 [95% CI, 1.11-1.70]; P = .004) were more likely to receive a diagnosis of RA-ILD during a hospitalization. Patients who received a diagnosis of RA-ILD during a hospitalization showed an increased hazard for future RA-ILD-related admissions (hazard ratio, 1.44 [1.24-1.68]; P < .001).
Interpretation: All-cause and RA-ILD-related hospitalizations are increasing. In-hospital mortality has not changed over time, but remains substantial. Socioeconomic factors are associated with receiving an RA-ILD diagnosis in the hospital, which seems to be an important risk factor for future RA-ILD-related admissions.
期刊介绍:
At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.